Switch theme
Sign up to access all valuation multiples
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.
2006
108
LTM Revenue $54.0M
LTM EBITDA -$28.0M
-$9.5M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Precision BioSciences has a last 12-month revenue of $54.0M and a last 12-month EBITDA of -$28.0M.
In the most recent fiscal year, Precision BioSciences achieved revenue of $68.7M and an EBITDA of $13.5M.
Precision BioSciences expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Precision BioSciences valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $48.7M | $68.7M | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$32.0M | $13.5M | XXX | XXX | XXX |
| EBITDA Margin | -66% | 20% | XXX | XXX | XXX |
| Net Profit | -$112M | -$61.3M | XXX | XXX | XXX |
| Net Margin | -229% | -89% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Precision BioSciences's stock price is $4.
Precision BioSciences has current market cap of $46.7M, and EV of -$9.5M.
See Precision BioSciences trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$9.5M | $46.7M | XXX | XXX | XXX | XXX | $-1.40 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Precision BioSciences has market cap of $46.7M and EV of -$9.5M.
Precision BioSciences's trades at -0.2x LTM EV/Revenue multiple, and 0.3x LTM EBITDA.
Analysts estimate Precision BioSciences's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Precision BioSciences and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | -$9.5M | XXX | XXX | XXX |
| EV/Revenue | -0.1x | XXX | XXX | XXX |
| EV/EBITDA | -0.7x | XXX | XXX | XXX |
| P/E | 6.5x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | 0.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpPrecision BioSciences's NTM/LTM revenue growth is -65%
Precision BioSciences's revenue per employee for the last fiscal year averaged $0.6M, while opex per employee averaged $0.9M for the same period.
Over next 12 months, Precision BioSciences's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Precision BioSciences's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Precision BioSciences and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 41% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 20% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -142% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -45% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.6M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.9M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 51% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 87% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 138% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Precision BioSciences acquired XXX companies to date.
Last acquisition by Precision BioSciences was XXXXXXXX, XXXXX XXXXX XXXXXX . Precision BioSciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Precision BioSciences founded? | Precision BioSciences was founded in 2006. |
| Where is Precision BioSciences headquartered? | Precision BioSciences is headquartered in United States of America. |
| How many employees does Precision BioSciences have? | As of today, Precision BioSciences has 108 employees. |
| Who is the CEO of Precision BioSciences? | Precision BioSciences's CEO is Mr. Michael Amoroso. |
| Is Precision BioSciences publicy listed? | Yes, Precision BioSciences is a public company listed on NAS. |
| What is the stock symbol of Precision BioSciences? | Precision BioSciences trades under DTIL ticker. |
| When did Precision BioSciences go public? | Precision BioSciences went public in 2019. |
| Who are competitors of Precision BioSciences? | Similar companies to Precision BioSciences include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Precision BioSciences? | Precision BioSciences's current market cap is $46.7M |
| What is the current revenue of Precision BioSciences? | Precision BioSciences's last 12-month revenue is $54.0M. |
| What is the current EBITDA of Precision BioSciences? | Precision BioSciences's last 12-month EBITDA is -$28.0M. |
| What is the current EV/Revenue multiple of Precision BioSciences? | Current revenue multiple of Precision BioSciences is -0.2x. |
| What is the current EV/EBITDA multiple of Precision BioSciences? | Current EBITDA multiple of Precision BioSciences is 0.3x. |
| What is the current revenue growth of Precision BioSciences? | Precision BioSciences revenue growth between 2023 and 2024 was 41%. |
| Is Precision BioSciences profitable? | Yes, Precision BioSciences is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
